公开(公告)号：US10721993B2

公开(公告)日：2020-07-28

申请号：US15813613

申请日：2017-11-15

Applicant: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE ,  THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

Inventor： Noah J. Rosenblatt ,  Ryan Crews ,  Farid Amirouche

IPC: A43B17/03 ,  A43B13/20 ,  A43B3/00 ,  A43B17/02 ,  G05B15/02

Abstract: A plantar surface pressure offloading system includes an insole capable of coupling with a shoe and interfacing with a foot. A number of compressible bladders and pressure sensors are coupled to the insole. Each bladder has an adjustable compressibility, and each pressure sensor is configured to measure a pressure exerted on a respective portion of the foot. A controller of the system can perform, for each compressible bladder, a compressibility adjustment process including (i) receiving, from a respective pressure sensor associated with a respective bladder, a signal indicative of a pressure exerted on a respective portion of the foot, (ii) determining, based on the signal, that the pressure exerted on the respective portion of the foot exceeds a threshold pressure, and (iii) responsive to the determination, adjusting the compressibility of the respective bladder, thereby offloading pressure from the respective portion of the foot to a different portion of the foot.

公开(公告)号：US10544417B2

公开(公告)日：2020-01-28

申请号：US15835995

申请日：2017-12-08

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： Michelle L. Hastings

IPC: C12N15/113

Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.

公开(公告)号：US10525076B2

公开(公告)日：2020-01-07

申请号：US15835698

申请日：2017-12-08

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： Michelle L. Hastings

IPC: A61K31/712 ,  C12N15/113

Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.

公开(公告)号：US10070648B2

公开(公告)日：2018-09-11

申请号：US15483987

申请日：2017-04-10

Applicant: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE

Inventor： Kwang Poo Chang ,  Bala Krishna Kolli ,  Shin-Hong Shiao

IPC: A01N55/02 ,  A01N43/90 ,  A01N55/00

CPC classification number: A01N55/02 ,  A01N43/90 ,  A01N55/00

Abstract: Disclosed herein are photodynamic insecticide methods and compositions for the control or reduction of insect populations comprising the use of photosensitizer compounds in combination with light.

公开(公告)号：US09970056B2

公开(公告)日：2018-05-15

申请号：US14870960

申请日：2015-09-30

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： Judith Ann Potashkin ,  Jose Alfredo Santiago

IPC: C12Q1/68

CPC classification number: C12Q1/6883 ,  C12Q2600/158

Abstract: Network-based meta-analysis of four independent microarray studies identified the hepatocyte nuclear factor (HNF4A), a transcription factor associated with gluconeogenesis and diabetes, as a central regulatory hub gene upregulated in blood of PD patients. In parallel, the polypyrimidine tract binding protein 1 (PTBP1), involved in the stabilization and mRNA translation of insulin, was identified as the most downregulated gene. Using both markers, PD patients were classified with 90% sensitivity and 80% specificity. Longitudinal performance analysis demonstrated that relative abundance of HNF4A and PTBP1 mRNAs significantly decreased and increased, respectively, in PD patients during 3 years follow up period. The inverse regulation of HNF4A and PTBP1 provides a molecular rationale for the altered insulin signaling observed in PD patients. The longitudinally dynamic biomarkers identified in this study may be useful for monitoring disease-modifying therapies for PD.

公开(公告)号：US20180119152A1

公开(公告)日：2018-05-03

申请号：US15835995

申请日：2017-12-08

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： Michelle L. HASTINGS

IPC: C12N15/113

Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.

公开(公告)号：US20180094266A1

公开(公告)日：2018-04-05

申请号：US15837926

申请日：2017-12-11

Applicant: Rosalind Franklin University of Medicine and Science ,  The McLean Hospital Corporation

Inventor： Michelle L. HASTINGS ,  Ole ISACSON ,  Joanna A. KORECKA-ROET

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/346 ,  C12N2320/33 ,  C12Y207/11001 ,  C12N2310/321 ,  C12N2310/3521 ,  C12N2310/3525 ,  C12N2310/322 ,  C12N2310/3533

Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Parkinson's disease.

公开(公告)号：US09840709B2

公开(公告)日：2017-12-12

申请号：US15045999

申请日：2016-02-17

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： Michelle L. Hastings

IPC: C12N15/11 ,  C12N15/113

CPC classification number: C12N15/1137 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/32 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/351 ,  C12N2310/3521 ,  C12N2310/3525 ,  C12N2310/3533 ,  C12N2320/30 ,  C12N2320/33

Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.

公开(公告)号：US20160244767A1

公开(公告)日：2016-08-25

申请号：US15045999

申请日：2016-02-17

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： Michelle L. HASTINGS

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/32 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/351 ,  C12N2310/3521 ,  C12N2310/3525 ,  C12N2310/3533 ,  C12N2320/30 ,  C12N2320/33

Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.

Abstract translation: 本公开一般涉及包含与囊性纤维化跨膜传导调节子（CFTR）RNA转录物互补的寡核苷酸的化合物。 某些这样的化合物可用于与CFTR RNA转录物杂交，包括但不限于细胞中的CFTR RNA转录物。 在某些实施方案中，这种杂交导致调节CFTR转录物的剪接。 在某些实施方案中，这些化合物用于治疗与囊性纤维化相关的一种或多种症状。

公开(公告)号：US20160024038A1

公开(公告)日：2016-01-28

申请号：US14716138

申请日：2015-05-19

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： Grace E. Stutzmann ,  Russell Dahl ,  Christopher H. Kaiho

IPC: C07D307/54 ,  C07D307/52 ,  C07D405/12

CPC classification number: C07D307/54 ,  C07D307/52 ,  C07D405/12 ,  C07D407/12

Abstract: Disclosed herein are methods and compositions comprising compounds capable of normalizing neuronal calcium dyshomeostasis. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, Pick's disease, chronic traumatic encepholopathy, traumatic brain injury, stroke, cerebellar ataxia, multiple sclerosis, Down syndrome, and aging-related CNS disorders.

Abstract translation: 本文公开了包含能够使神经元钙发育不稳定性归一化的化合物的方法和组合物。 还公开了包括这些化合物用于治疗神经元或神经障碍的方法，包括阿尔茨海默病，帕金森病，亨廷顿舞蹈病，颞叶性痴呆，皮克病，慢性创伤性脑病，创伤性脑损伤，中风，小脑共济失调，多发性硬化症，唐氏综合征 ，和老化相关的中枢神经系统疾病。